Calithera Biosciences
Developing novel small molecule therapeutics for the treatment of cancer.
Launch date
Employees
Market cap
€221k
Enterprise valuation
(€1m) (Public information from Sep 2024)
Share price
$0.02 CALA
South San Francisco California (HQ)
Financials
Estimates*
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 26.0m | 22.0m | - | - | 9.8m | - |
| % growth | - | - | (15 %) | - | - | - | - |
| EBITDA | - | - | - | (92.9m) | (91.4m) | (13.7m) | (43.8m) |
| % EBITDA margin | - | - | - | - | - | (140 %) | - |
| Profit | - | (27.0m) | (54.0m) | (89.9m) | (90.1m) | (115m) | (39.6m) |
| % profit margin | - | (104 %) | (245 %) | - | - | (1180 %) | - |
| EV / revenue | - | 5.1x | 0.8x | - | - | -0.7x | - |
| EV / EBITDA | - | - | - | -1.7x | -2.6x | 0.5x | 0.2x |
| R&D budget | 28.6m | - | 41.8m | 76.3m | 71.0m | 53.5m | 28.5m |
| R&D % of revenue | - | - | 190 % | - | - | 548 % | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$40.0m | Series A | ||
| N/A | $8.0m | Series B | |
$2.0m | Series C | ||
$35.0m | Series D | ||
$16.0m | Series D | ||
| N/A | N/A | IPO | |
* | N/A | $80.5m | Post IPO Equity |
* | N/A | $50.0m | Post IPO Equity |
| N/A | $57.5m | Post IPO Equity | |
| N/A | $36.0m | Post IPO Equity | |
$2.4m | Grant | ||
* | N/A | $10.0m | Post IPO Equity |
| Total Funding | €94.0m | ||
Related Content
Recent News about Calithera Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.